XML 110 R23.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2015
Segment Reporting [Abstract] |
Segment Information | Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products in the United States. This segment also operates nuclear pharmacies and cyclotron facilities, provides pharmacy operations, medication therapy management and patient outcomes services to hospitals and other healthcare providers, provides services to healthcare companies supporting the marketing, distribution and payment for specialty pharmaceutical products and manufactures and repackages generic pharmaceuticals and over-the-counter healthcare products. This segment also imports and distributes pharmaceuticals, over-the-counter healthcare and consumer products as well as provides specialty pharmacy and other services in China. The Medical segment distributes a broad range of medical, surgical and laboratory products and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States, Canada and China and to patients in the home in the United States. This segment also manufactures, sources and develops our own Cardinal Health brand medical and surgical products, which are sold directly or through third-party distributors in the United States, Canada, Europe and other regions internationally. The following tables present revenue for each reportable segment and Corporate:
(in millions) | 2015 |  | 2014 |  | 2013
Pharmaceutical (1) | $ | 91,116 |  |  | $ | 80,110 |  |  | $ | 91,097 |
Medical | 11,395 |  |  | 10,962 |  |  | 10,060 |
Total segment revenue | 102,511 |  |  | 91,072 |  |  | 101,157 |
Corporate (2) | 20 |  |  | 12 |  |  | (64 | )
Total revenue | $ | 102,531 |  |  | $ | 91,084 |  |  | $ | 101,093 |
(1) | Our pharmaceutical distribution contract with Walgreen Co. expired on August 31, 2013.
(2) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
We evaluate segment performance based upon segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment SG&A expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance. Corporate expenses are allocated to the segments based upon headcount, level of benefit provided and other ratable allocation methodologies. We do not allocate the following items to our segments: LIFO inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other income, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. We did not recognize any LIFO charges or credits during fiscal 2015, 2014, or 2013. In addition, certain investment and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $26 million, $33 million and $37 million for fiscal 2015, 2014 and 2013, respectively. Beginning in fiscal 2016, we are changing our methodology for allocating certain portions of enterprise-wide incentive compensation expenses among Corporate and the segments. This change does not impact consolidated operating earnings or net earnings. The following tables present segment profit by reportable segment and Corporate:
(in millions) | 2015 |  | 2014 |  | 2013
Pharmaceutical | $ | 2,094 |  |  | $ | 1,745 |  |  | $ | 1,734 |
Medical | 433 |  |  | 444 |  |  | 372 |
Total segment profit | 2,527 |  |  | 2,189 |  |  | 2,106 |
Corporate | (366 | ) |  | (304 | ) |  | (1,110 | )
Total operating earnings | $ | 2,161 |  |  | $ | 1,885 |  |  | $ | 996 |
The following tables present depreciation and amortization and additions to property and equipment by reportable segment and at Corporate:
(in millions) | 2015 |  | 2014 |  | 2013
Pharmaceutical | $ | 124 |  |  | $ | 128 |  |  | $ | 125 |
Medical | 119 |  |  | 130 |  |  | 137 |
Corporate | 208 |  |  | 201 |  |  | 135 |
Total depreciation and amortization | $ | 451 |  |  | $ | 459 |  |  | $ | 397 |
(in millions) | 2015 |  | 2014 |  | 2013
Pharmaceutical | $ | 90 |  |  | $ | 72 |  |  | $ | 46 |
Medical | 87 |  |  | 72 |  |  | 48 |
Corporate | 123 |  |  | 105 |  |  | 101 |
Total additions to property and equipment | $ | 300 |  |  | $ | 249 |  |  | $ | 195 |
The following table presents total assets for each reportable segment and Corporate at June 30:
(in millions) | 2015 |  | 2014 |  | 2013
Pharmaceutical | $ | 17,385 |  |  | $ | 15,361 |  |  | $ | 16,258 |
Medical | 7,095 |  |  | 6,768 |  |  | 6,521 |
Corporate | 5,662 |  |  | 3,904 |  |  | 3,040 |
Total assets | $ | 30,142 |  |  | $ | 26,033 |  |  | $ | 25,819 |
The following tables present revenue and property and equipment, net by geographic area:
(in millions) | 2015 |  | 2014 |  | 2013
United States | $ | 98,435 |  |  | $ | 87,449 |  |  | $ | 97,994 |
International | 4,096 |  |  | 3,635 |  |  | 3,099 |
Total revenue | $ | 102,531 |  |  | $ | 91,084 |  |  | $ | 101,093 |
(in millions) | 2015 |  | 2014 |  | 2013
United States | $ | 1,327 |  |  | $ | 1,301 |  |  | $ | 1,355 |
International | 179 |  |  | 158 |  |  | 134 |
Property and equipment, net | $ | 1,506 |  |  | $ | 1,459 |  |  | $ | 1,489 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration